Format

Send to

Choose Destination
Biosci Rep. 2019 Jan 11;39(1). pii: BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31.

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Author information

1
Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A.
2
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, U.S.A.
3
The Second Affiliated Hospital, Cardiovascular Key Laboratory of Zhejiang Province, Department of Cardiology, College of Medicine, Zhejiang University, Hangzhou, China.
4
Ionis Pharmaceuticals, Inc., Carlsbad, CA, U.S.A.
5
Department of Physiology, University of Kentucky, Lexington, KY, U.S.A.
6
Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A. Hong.Lu@uky.edu.

Abstract

Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.

KEYWORDS:

angiotensinogen; antisense oligonucleotides; cardiovascular disease; hypertension

PMID:
30530571
PMCID:
PMC6328882
DOI:
10.1042/BSR20180201
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center